235 related articles for article (PubMed ID: 10566038)
41. BTI 322. Anti-CD2 monoclonal antibody, Lo-CD2-a, monoclonal antibody Lo-CD2-a.
Drugs R D; 1999 Jan; 1(1):68-70. PubMed ID: 10565990
[No Abstract] [Full Text] [Related]
42. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
43. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
44. Golimumab for moderate to severe ulcerative colitis.
Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
[TBL] [Abstract][Full Text] [Related]
45. Balancing the risks and benefits of prolonged use of infliximab.
Schölmerich J
Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
[No Abstract] [Full Text] [Related]
46. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F
Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
[No Abstract] [Full Text] [Related]
47. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
Teixeira FV; Kotze PG; Damião AO; Miszputen SJ
Arq Gastroenterol; 2015; 52(1):76-80. PubMed ID: 26017088
[TBL] [Abstract][Full Text] [Related]
48. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Heidemann J; Kucharzik T
Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
[No Abstract] [Full Text] [Related]
49. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
[TBL] [Abstract][Full Text] [Related]
50. Novel treatments for inflammatory bowel disease.
Lee HS; Park SK; Park DI
Korean J Intern Med; 2018 Jan; 33(1):20-27. PubMed ID: 29223139
[TBL] [Abstract][Full Text] [Related]
51. [Disseminated salmonella infection with aortic mycotic aneurysm in a ulcerative colitis patient treated with infliximab].
Corberand D; Bredin C; Gizard E; Sava C; Rey P
Presse Med; 2013 Dec; 42(12):1658-60. PubMed ID: 23688701
[No Abstract] [Full Text] [Related]
52. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Lee TW; Fedorak RN
Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
[TBL] [Abstract][Full Text] [Related]
53. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
Chang JT; Lichtenstein GR
Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
[TBL] [Abstract][Full Text] [Related]
54. Infliximab for ulcerative colitis.
Simmons J; Jewell DP
Dig Liver Dis; 2002 Sep; 34(9):616-8. PubMed ID: 12405245
[No Abstract] [Full Text] [Related]
55. Inflammatory bowel disease: short- and long-term treatments.
Bickston SJ; Cominelli F
Adv Intern Med; 1998; 43():143-74. PubMed ID: 9506181
[No Abstract] [Full Text] [Related]
56. How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes.
St-Pierre J; Chadee K
Dig Dis Sci; 2014 Apr; 59(4):712-5. PubMed ID: 24504593
[No Abstract] [Full Text] [Related]
57. Anti-tumor necrosis factor therapy for ulcerative colitis.
Kountouras J; Zavos C; Chatzopoulos D
Gastroenterology; 2005 Sep; 129(3):1138-9. PubMed ID: 16143158
[No Abstract] [Full Text] [Related]
58. [Therapy of chronic inflammatory bowel diseases].
Stange EF
Praxis (Bern 1994); 2002 Nov; 91(47):2029-39. PubMed ID: 12501498
[TBL] [Abstract][Full Text] [Related]
59. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
[TBL] [Abstract][Full Text] [Related]
60. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
Sipponen T; Kolho KL
Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
